Novartis looks set to repurpose cancer drug in MS after tria...

Novartis has announced data supporting a cancer drug it acquired from GlaxoSmithKline and Genmab in a new use in multiple sclerosis, with plans for regulatory filings later this year.

AbbVie axes multi-billion cancer flop Rova-T after another t...

AbbVie has axed its troubled lung cancer drug Rova-T, after another trial failure from the drug that is turning out to be an expensive flop, costing almost $10 billion so far.

Could phase 3 trial win save AZ's troubled Lupus drug?

AstraZeneca has been on a hot streak of trial successes recently, with the latest win being in a late-stage study for a potential lupus drug that looked dead and buried after a major trial

GSK takes option to license hepatitis B RNA drugs from Ionis

GlaxoSmithKline has taken an option to license Ionis’ antisense medicines for people with chronic hepatitis B virus infection after supportive phase 2 trial results.

FDA fast-tracks AZ's Farxiga in potential new CKD indication

The FDA has fast-tracked AstraZeneca’s Farxiga in a potential new use, to delay progression of renal failure and prevent cardiovascular death and renal death in patients with chronic kidney

Low-cost polypill could dramatically cut heart attacks, stro...